The Topic of the proposed article collection for Frontiers in Endocrinology concerns adiponectin, one of the major adipokines. Adiponectin has been first described as a beneficial cytokine exhibiting insulin-sensitizing, anti-inflammatory, antiatherogenic activities, and even anti-cancer properties. Numerous in vitro and animal studies continue to validate these claims. However, new evidence also suggested that, paradoxically, elevated adiponectin levels can be associated with induction or existence of some pathologies.
The Topic Editors, representing basic, translational and clinical science disciplines, strongly believe that research and medical communities interested in adiponectin will benefit from a well organized and updated discussion forum tackling the multifaceted nature of this protein and the challenges associated with a potential pharmaceutical development. This planned collection of peer-reviewed articles will highlight the complexity of adiponectin biology, focusing on different diseases and/ or sites of action. We also plan to explore the data suggesting the utility of adiponectin as biomarker and biotarget.
We are interested in manuscripts (reviews or original research) that will fall into the following subtopics:
1. Adiponectin signaling updates (tissue specificity, crosstalk with other pathways);
2. Adiponectin in metabolic diseases (update on diabetes, obesity, and comorbidities);
3. Adiponectin in CVD (update on potential negative effects);
4. Adiponectin in inflammation (update on potential pro-inflammatory actions);
5. Adiponectin in cancer (update on potential use as biomarker and biotarget);
6. Adiponectin in CNS and ophthalmic systems;
7. Adiponectin as biotarget and biomarker.
Conflict of Interests Statement:
Dr. Surmacz serves on the Scientific Advisory Board of Allysta Pharmaceuticals. The company is developing compounds targeting adiponectin pathways but is not involved in any aspect of the work of Dr. Surmacz as a Topic Editor.
The Topic of the proposed article collection for Frontiers in Endocrinology concerns adiponectin, one of the major adipokines. Adiponectin has been first described as a beneficial cytokine exhibiting insulin-sensitizing, anti-inflammatory, antiatherogenic activities, and even anti-cancer properties. Numerous in vitro and animal studies continue to validate these claims. However, new evidence also suggested that, paradoxically, elevated adiponectin levels can be associated with induction or existence of some pathologies.
The Topic Editors, representing basic, translational and clinical science disciplines, strongly believe that research and medical communities interested in adiponectin will benefit from a well organized and updated discussion forum tackling the multifaceted nature of this protein and the challenges associated with a potential pharmaceutical development. This planned collection of peer-reviewed articles will highlight the complexity of adiponectin biology, focusing on different diseases and/ or sites of action. We also plan to explore the data suggesting the utility of adiponectin as biomarker and biotarget.
We are interested in manuscripts (reviews or original research) that will fall into the following subtopics:
1. Adiponectin signaling updates (tissue specificity, crosstalk with other pathways);
2. Adiponectin in metabolic diseases (update on diabetes, obesity, and comorbidities);
3. Adiponectin in CVD (update on potential negative effects);
4. Adiponectin in inflammation (update on potential pro-inflammatory actions);
5. Adiponectin in cancer (update on potential use as biomarker and biotarget);
6. Adiponectin in CNS and ophthalmic systems;
7. Adiponectin as biotarget and biomarker.
Conflict of Interests Statement:
Dr. Surmacz serves on the Scientific Advisory Board of Allysta Pharmaceuticals. The company is developing compounds targeting adiponectin pathways but is not involved in any aspect of the work of Dr. Surmacz as a Topic Editor.
